He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more. Chapters The hub and spoke model - 0:41 Equity structure - 5:43 Putt

Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more. Chapters Championing innovation - 1:12 Oligos and RNAi today - 5:41 China - 16:20 Me-too and differentiation - 19:11 Drug pricing and access

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He...

Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his...

One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs,...

For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and...